Eva Pers Winning Iepsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2816698/publications.pdf

Version: 2024-02-01

1039880 1125617 15 658 9 13 g-index citations h-index papers 15 15 15 1294 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A Gut-Intrinsic Melanocortin Signaling Complex Augments L-Cell Secretion in Humans. Gastroenterology, 2021, 161, 536-547.e2.	0.6	10
2	Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?. Cardiovascular Research, 2021, 117, e120-e122.	1.8	3
3	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. Journal of Bone and Mineral Metabolism, 2020, 38, 117-125.	1.3	7
4	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Reports Medicine, 2020, 1, 100006.	3.3	22
5	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metabolism, 2018, 28, 23-32.e3.	7.2	88
6	Patients With Long-QT Syndrome Caused by Impaired <i>hERG</i> -Encoded K _v 11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia. Circulation, 2017, 135, 1705-1719.	1.6	33
7	Glucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects. Heart Rhythm, 2017, 14, 1165-1170.	0.3	8
8	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Molecular Systems Biology, 2016, 12, 901.	3.2	188
9	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. Metabolomics, 2016, 12, 1.	1.4	O
10	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3–36. European Journal of Endocrinology, 2016, 174, 775-784.	1.9	72
11	Major rapid weight loss induces changes in cardiac repolarization. Journal of Electrocardiology, 2016, 49, 467-472.	0.4	12
12	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2909-2917.	1.8	116
13	Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Review of Cardiovascular Therapy, 2015, 13, 753-767.	0.6	62
14	Response to the Letter by Kizilgul M., et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L72-L72.	1.8	0
15	Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opinion on Pharmacotherapy, 2014, 15, 2487-2500.	0.9	37